Author:
Sangsai Onpawee,Aueaphatthanawong Kamonchanok
Abstract
Objective: Individuals with Idiopathic Inflammatory Central Nervous System Demyelinating Diseases (CNS-IIDDs) have an elevated risk for infection. Vaccination is key to reducing infection. This study aimed to determine vaccination coverage, the adverse effects of vaccination, and general vaccination knowledge in the patients.
Methods and Methods: A single-center cross-sectional study in the Multiple Sclerosis Clinic at Siriraj Hospital, Thailand, was performed using the designed questionnaires.
Results: Of 100 participants, 90% were female, with a mean (SD) age of 46.2 (12.9). Overall, all received compulsory vaccine coverage. For optional vaccines, the coverage was lower-than-expected, with rates of 3%, 4%, and 3% for human papilloma virus, pneumococcal, and zoster vaccines, respectively. Only 28% of participants received the 2021/2022 seasonal influenza vaccine. The only factor associated with the uptake of the influenza vaccination was the participants’ health coverage. By asking questions to evaluate general vaccination knowledge, two questions related to vaccination and immuno-suppressive agents received the highest percentage of ‘not sure’ responses.
Conclusion: Vaccination coverage was lower than expected among Thai CNS-IIDDs patients, both for optional and seasonal influenza vaccines. Vaccination in these groups of patients should be encouraged to prevent potential infections.
Publisher
Faculty of Medicine Siriraj Hospital, Mahidol University
Reference21 articles.
1. Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;89(10):1050-6.
2. Swart EC, Mager D, Parekh N, Heyman RA, Henderson R, Munshi K, et al. Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy. Mult Scler Relat Disord. 2021;56:103285.
3. Zhao Z, Ma C-L, Gu Z-C, Dong Y, Lv Y, Zhong M-K. Incidence and risk of infection associated with fingolimod in patients with multiple sclerosis: a systematic review and meta-analysis of 8,448 patients from 12 randomized controlled trials. Front Immunol. 2021;12:611711.
4. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 2013;20(8):1153-60.
5. Thailand TRCoPo. Recommended adult and elderly immunization schedule 2011 [cited 2022 19 September]. Available from: http://www.rcpt.org/index.php/2012-10-03-16-53-39/category/6-2013-02-02-09-02-52.html?download=56%3A2013-02-02-09-08-53.